Bavarian Nordic Q1 revenue falls as Public Preparedness unit sales decline

Bavarian Nordic A/S

13/05/2026 06:44

Overview

Denmark vaccine maker's Q1 revenue fell yr/yr as Public Preparedness sales declined as expected

Travel Health revenue up 14% yr/yr, driven by rabies and chikungunya vaccine demand

Company completed DKK 350 mln share buybacks during 2026

Outlook

Bavarian Nordic maintains 2026 revenue guidance at DKK 5,500–5,700 mln

Company expects 2026 EBITDA margin of approximately 28%

Company expects Public Preparedness revenue above DKK 1.5–2 bln base level in 2026

Result Drivers

TRAVEL HEALTH GROWTH - Co said 14% yr/yr growth in Travel Health revenue was driven by increased demand for rabies vaccines and continued launch of chikungunya vaccine

PUBLIC PREPAREDNESS DECLINE - Public Preparedness revenue fell 53% yr/yr, which co said was expected as 2026 is a normalized year without material mpox outbreak impact

Company press release: ID:nGNE2kHGyk

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
DKK 1.06 bln
Q1 EBITDA
DKK 165 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Bavarian Nordic A/S is DKK270.00, about 36.1% above its May 12 closing price of DKK198.40

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)